Category: Clinical Trials - Psychedelic Alpha

Our 2022 Year in Review is now live.

Psilocybin for Depression Study Approved and Funded by German Government

Post published:November 19, 2020
Post category:Clinical Trials News

Single Dose of Psilocybin Reduces Migraines for at Least 2 Weeks

Post published:November 14, 2020
Post category:Clinical Trials Research

Read more about the article Phase 2 Clinical Trial to Evaluate Safety and Efficacy of Psilocybin in Cancer Patients with Major Depressive Disorder

Phase 2 Clinical Trial to Evaluate Safety and Efficacy of Psilocybin in Cancer Patients with Major Depressive Disorder

Post published:October 22, 2020
Post category:Clinical Trials News

First Psilocybin for Depression Clinical Trial Launched in Sweden

Post published:October 16, 2020
Post category:Clinical Trials News

Can Taking MDMA with LSD Help Prevent a ‘Bad Trip’? New Clinical Trial Investigates

Post published:August 19, 2020
Post category:Clinical Trials News

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Insights and interviews delivered to your inbox. No spam, just valuable information.

Weekly Bulletin

Your weekly recap of news and analysis from the psychedelic sector.

Research Review

A monthly review of the most important psychedelics research.

News & Interviews

The latest news from across the psychedelics space.

Psychedelics Patent Trackers

We track the latest patents and filings related to psilocybin, MDMA and DMT.

Psychedelic Legalization & Decriminalization Tracker

Mapping psychedelic drug policy reform across the United States

Psychedelics Drug Development Tracker

From drug discovery to regulatory approval, we map drug development in psychedelics.

Stocks & Companies Directory

A directory of all the major psychedelics stocks, companies and ETFs.

Sector Landscape Map

Explore the Psychedelic Sector Landscape visually using our new tool.

Stock Watchlist

A one-stop overview of psychedelics stocks financial performance.

Psilocybin for Depression Study Approved and Funded by German Government

Single Dose of Psilocybin Reduces Migraines for at Least 2 Weeks

Phase 2 Clinical Trial to Evaluate Safety and Efficacy of Psilocybin in Cancer Patients with Major Depressive Disorder

First Psilocybin for Depression Clinical Trial Launched in Sweden

Can Taking MDMA with LSD Help Prevent a ‘Bad Trip’? New Clinical Trial Investigates

Psychedelic Alpha

Quick Links

Newsletter

Join Our Newsletter

Psychedelic sector insights, interviews and analysis delivered to your inbox.

No thanks, continue to site.